BMS Reacquisition Bulks Up ASLAN’s Deal Chest
Singapore's ASLAN has licensed back to originator BMS the Asian rights to a novel oncology molecule with potential as both a mono and combination therapy, boosting funding for potential future deals in the process.
You may also be interested in...
Amid recent progress for its lead molecule, ASLAN has firmed up plans for the timing of its initial public offering, which is now expected to take place in Taiwan mid May with the newly listed shares set to begin trading in early June.
Singapore's ASLAN has signed its second deal in the past few weeks, acquiring global rights to an early stage immuno-oncology molecule that helps to fill a pipeline hole left by a recent out-licensing deal with Bristol-Myers Squibb.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.